Test Questions

Optimizing Individualized Management of Osteoarthritis

Exam Questions

1. What is the lifetime risk for OA among people in the United States?
    A. 9.5%
    B. 14.4%
    C. 22.6%
    D. 44.7%
2. The most common site of OA is:
    A. Knee
    B. Hip
    C. Spine
    D. Fingers
3. Which of the following is not a common symptom of OA?
    A. Allodynia
    B. Crepitus
    C. Stiffness
    D. Limitation in range of motion
4. Which of the following risk factors is least strongly associated with the development of OA?
    A. Obesity
    B. Older age
    C. Exercise
    D. History of joint injury
5. Secondary causes of OA include all of the following except:
    A. Gout
    B. Renal insufficiency
    C. Acromegaly
    D. Hemochromatosis
6. The percentage of OA patients with some degree of movement limitation is:
    A. 20%
    B. 40%
    C. 60%
    D. 80%
7. Abnormal stress in the joint of a patient with OA can result in production of inflammatory cytokines including which of the following?
    A. TNF-α
    B. Interferon-γ
    C. PPAR-α
    D. ICAM-1
8. Which of the following molecules is thought to stimulate abnormal angiogenesis in the joints of OA patients?
    A. EGF
    B. TGF-β
    C. IL-11
    D. VEGF
9. Which of the following is generally considered to be first-line treatment for pain in patients with OA?
    A. Acetaminophen
    B. Ibuprofen
    C. Celecoxib
    D. Tramadol
10. The most concerning adverse effect associated with acetaminophen use is?
    A. Cardiac toxicity
    B. Hepatotoxicity
    C. Gastrointestinal bleeding
    D. Prolonged bleeding time
11. The use of non-selective NSAIDs is associated with gastrointestinal bleeding in what percentage of patients:
    A. 1-3%
    B. 3-5%
    C. 5-7%
    D. 7-9%
12. Which statement accurately describes the risks and benefits of NSAID and selective COX-2 inhibitor use?
    A. COX-2 inhibitors have improved efficacy over NSAIDs
    B. NSAIDs have improved efficacy over COX-2 inhibitors
    C. Concomitant use of low-dose aspirin may negate gastroprotective effects of NSAIDs
    D. Concomitant use of low-dose aspirin may negate gastroprotective effects of COX-2 inhibitors
13. Which of the following is not a common side effect of tramadol?
    A. Constipation
    B. Nausea
    C. Dizziness
    D. Rash
14. Which of the following statements about topical capsaicin is true?
    A. Its use may result in allodyni
    B. It has no effect on nerve fiber density in the skin.
    C. It has not yet been shown to be effective for the treatment of OA-related pain.
    D. It should only be used for short-term therapy.
15. Which analgesic does The Working Group on Pain Management recommend avoiding for patients with cardiac or renal disease?
    A. Topical Capsaicin
    B. Oral Ibuprofen
    C. Topical Lidocaine
    D. Oral Morphine
16. Tolerance to which of the following adverse effects related to opioid analgesics does NOT occur?
    A. Constipation
    B. Dizziness
    C. Itching
    D. Sedation
17. Which of the following medication classes has been used with some efficacy via intraarticular administration for patients with OA pain?
    A. Anticonvulsants
    B. Local anesthetics
    C. Opioids
    D. Tricyclic antidepressants
18. Successful strategies to reduce the risk of abuse include all of the following except:
    A. Extended release formulations
    B. Patient adherence agreements
    C. Adherence monitoring programs
    D. Patient self-reporting
19. Which class of analgesic has the highest level of evidence for efficacy according to the OARSI guidelines?
    A. Opiates
    B. Topical analgesics
    C. Tramadol
    D. Glucosamine and chondroitin
20. Nutraceuticals with proven efficacy in treating OA include each of the following except:
    A. Glucosamine
    B. Chondroitin
    C. Ginger
    D. Avocado and soybean

Evaluation Questions

21. In questions 21-25 rate the effectiveness of how well the activity met the stated learning objectives: Met objective 1:
    A. Excellent
    B. Very Good
    C. Good
    D. Fair
    E. Poor
    F. N/A for Pharmacy Technicians
22. Met objective 2:
    A. Excellent
    B. Very Good
    C. Good
    D. Fair
    E. Poor
    F.

N/A for Pharmacy Technicians
23. Met objective 3:
    A. Excellent
    B. Very Good
    C. Good
    D. Fair
    E. Poor
    F. N/A for Pharmacy Technicians
24. Met objective 4:
    A. Excellent
    B. Very Good
    C. Good
    D. Fair
    E. Poor
25. Related to your educational needs?
    A. Excellent
    B. Very Good
    C. Good
    D. Fair
    E. Poor
26. The active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
    A.

Excellent
    B.

Very Good
    C.

Good
    D. Fair
    E. Poor
27. Avoided commercial bias:
    A.

Excellent
    B.

Very Good
    C.

Good
    D. Fair
    E. Poor
28. How would you rate the oveall usefulness of the material presented?
    A.

Excellent
    B.

Very Good
    C.

Good
    D.

Fair
    E.

Poor
29. How would you rate the quality of the faculty?
    A. Excellent
    B. Very Good
    C. Good
    D. Fair
    E. Poor
30. How would you rate the appropriateness of the examination for this activity?
    A. Excellent
    B.

Very Good
    C. Good
    D. Fair
    E. Poor
31. Comments on this activity:
 
* Also applies to pharmacy technicians